Clinical Trial Update: Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update showing anti-tumor activity of SB-485232 in patients with previously untreated metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• SB-485232

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Phase 2 | Status: COMPLETED